SUPPLEMENTAL INDENTURE RELATED TO THE ASSUMPTIONSupplemental Indenture • October 9th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) dated as of October 4, 2012, among VALEANT PHARMACEUTICALS INTERNATIONAL, a Delaware corporation (the “Company”), VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the federal laws of Canada (“Parent”), the Subsidiary Guarantors party hereto (together with Parent, the “Guarantors”) and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association duly organized under the laws of the United States, as trustee under the Indenture referred to below (the “Trustee”).
JOINDER AGREEMENTJoinder Agreement • October 9th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This Joinder Agreement is dated as of October 2, 2012 (this “Agreement”), by and among the undersigned financial institutions (each a “New Term Loan Lender” and collectively the “New Term Loan Lenders”), Valeant Pharmaceuticals International, Inc., a corporation continued under the federal laws of Canada (“Borrower”), the undersigned subsidiaries of Borrower and Goldman Sachs Lending Partners LLC (“GSLP”), as Administrative Agent and Collateral Agent.
